Stocks and Investing Stocks and Investing
Thu, July 18, 2024

Rachel Vatnsdal Downgraded (TXG) to Hold and Decreased Target to $20 on, Jul 18th, 2024


Published on 2024-10-28 12:33:40 - WOPRAI, Rachel Vatnsdal
  Print publication without navigation


Rachel Vatnsdal of JP Morgan, Downgraded "10x Genomics, Inc." (TXG) to Hold and Decreased Target from $40 to $20 on, Jul 18th, 2024.

Rachel has made no other calls on TXG in the last 4 months.



There are 10 other peers that have a rating on TXG. Out of the 10 peers that are also analyzing TXG, 6 agree with Rachel's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Justin Bowers of "Deutsche Bank" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Wednesday, July 10th, 2024
  • Doug Schenkel of "Wolfe Research" Downgraded from Buy to Hold on, Thursday, June 27th, 2024
  • Subbu Nambi of "Guggenheim" Downgraded from Strong Buy to Hold on, Wednesday, June 26th, 2024
  • Tycho Peterson of "Jefferies" Initiated at Hold and Held Target at $24 on, Monday, June 3rd, 2024
  • Dan Brennan of "TD Cowen" Downgraded from Strong Buy to Hold and Decreased Target to $32 on, Wednesday, May 1st, 2024
  • Dan Leonard of "UBS" Maintained at Hold with Decreased Target to $30 on, Wednesday, May 1st, 2024


These are the ratings of the 4 analyists that currently disagree with Rachel


  • Daniel Arias of "Stifel" Maintained at Strong Buy with Decreased Target to $25 on, Tuesday, July 16th, 2024
  • Matthew Sykes of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $16 on, Tuesday, July 9th, 2024
  • Luke Sergott of "Barclays" Maintained at Buy with Decreased Target to $24 on, Friday, June 28th, 2024
  • Kyle Mikson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $50 on, Monday, April 29th, 2024
Contributing Sources